Sobi appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

STOCKHOLM, Oct. 5, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) today announced the appointment of Lydia Abad-Franch, MD, MBA as Senior Vice President, Head of Research, Development and Medical Affairs (RDMA), and Chief Medical Officer. Abad-Franch has been in this role on an interim basis since June.

"Lydia is both an accomplished leader in rare diseases and an esteemed practicing medical doctor," said Guido Oelkers, CEO of Sobi. "In addition, she has deep knowledge of the Sobi business as she has been with us for almost four years. This makes her the ideal RDMA leader for us as we continue building our pipeline to bring new medicines to patients, expand our existing products into new indications and regions where they address unmet medical needs, and gather real-world evidence for available products."

Lydia Abad-Franch said: "I am very excited to lead the research, development, and medical teams at Sobi, where we have a strong portfolio of transformative medicines for people with rare diseases. I look forward to working with my colleagues across Sobi, our external partners, patients, and physicians to advance science and address critical unmet needs of patients with rare diseases."

Dr Abad-Franch holds an M.D. from the School of Medicine, University of Valencia, Spain, and an MBA from the University Carlos III of Madrid, Spain. She brings extensive experience and knowledge from the global pharmaceutical industry as well as from being a practicing medical doctor and clinical investigator. Prior to joining Sobi in 2020, she led medical affairs teams for Baxter-Baxalta-Shire-Takeda, successfully introducing new innovative rare disease treatments after starting in the pharma industry as medical lead for Novo Nordisk. She will continue to report to CEO Guido Oelkers and be a member of the Sobi Executive Committee.

Sobi's R&D is focused on the late-stage development of treatments for haematology and immunology, developing new medicines as well as new indications, and expanding their global reach. Sobi has built an R&D pipeline of eight assets across twelve projects from phase 2 onwards through partnerships and acquisitions.

Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Tobias Cottmann [email protected], +41 79 287 10 51
Head of Investor Relations & External Communication (interim)

The following files are available for download: